MASH (metabolic dysfunction-associated steatohepatitis, the renamed NASH) is the liver disease that has emerged as the next major peptide drug indication after obesity. Both GLP-1s and dual/triple agonists have shown MASH benefit, with the mechanism question — direct hepatic effect versus weight-loss-mediated — only recently resolved.
The most cited 2026 read: a Cell Metabolism paper from Sinai Health pinned semaglutide's MASH reversal to liver sinusoidal endothelial cells (LSECs), which account for ~3% of liver cell volume but drive hepatoprotection. Mice without LSEC GLP-1 receptors saw no liver improvement despite 20% weight loss; mice without brain appetite receptors still reversed MASH. That decouples MASH benefit from weight loss for the first time.
Regulatory milestones followed. The FDA approved semaglutide for MASH with fibrosis in August 2025. On June 19, 2026, Japan's MHLW granted Novo Nordisk a partial change approval making Wegovy the first approved MASH treatment in Japan (without cirrhosis, moderate-to-advanced fibrosis), co-promoted with Sumitomo Pharma. The approval rests on ESSENCE Phase 3 Part 1 data showing semaglutide 2.4 mg superior to placebo on both liver fibrosis improvement and MASH resolution. Boehringer Ingelheim's survodutide full 48-week Phase 2 NEJM data (47-62% MASH improvement without fibrosis worsening) and Altimmune's pemvidutide 48-week IMPACT data at EASL 2026 added the GLP-1/glucagon dimension; the survodutide SYNCHRONIZE-1 Phase 3 readout is expected late 2026.
Stories here cover trial readouts, regulatory approvals, mechanism papers, and the broader liver-disease pipeline. See [[liver-disease]], [[liver]], [[essence-phase-3]], and [[survodutide]] for adjacent threads.
Japan's Ministry of Health, Labour and Welfare granted Novo Nordisk a partial change approval of the manufacturing and marketing authorization for Wegovy (semaglutide) subcutaneous injection on June 19, 2026, adding an indication for metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis in patients with moderate to advanced fibrosis (stage F2 or F3). Wegovy is now the first approved MASH treatment in Japan. The approval is based on Part 1 of the global Phase 3 ESSENCE study where semaglutide 2.4 mg demonstrated statistically significant superiority to placebo on the co-primary endpoints of liver fibrosis improvement without worsening of MASH, and MASH resolution without worsening of fibrosis. Wegovy is co-promoted in Japan by Novo Nordisk Pharma and Sumitomo Pharma under the October 2025 co-promotion agreement. This is the second major MASH regulatory milestone for semaglutide after the FDA's August 2025 approval.
MetaVia presented three Sunday June 7 posters at ADA 2026. The Phase 1 higher-dose cohort of DA-1726, the once-weekly dual GLP-1/glucagon oxyntomodulin analog, builds on the prior 32 mg multiple-ascending-dose readout that showed strong effects on weight, glucose, and waist. The GPR119 agonist vanoglipel was presented in two combinations: with resmetirom for synergistic hepatoprotective effects in MASH, and with metformin for joint glycemic and weight benefit.
MetaVia's three June 7 posters at ADA cover the higher-dose Part 3 cohort of its once-weekly dual GLP-1/glucagon agonist DA-1726, which previously cleared a 32 mg dose with strong weight, glucose, and waist effects in the multiple-ascending-dose study, and two combinations of its GPR119 agonist vanoglipel: with resmetirom for synergistic hepatoprotective effects in MASH, and with metformin for joint glycemic and weight benefit. The company is small-cap but its readouts add depth to both the dual-agonist and GPR119 threads.
EASL 2026 closed in Barcelona on May 30 after a week that reshaped two liver-disease narratives. On MASH: the GLP-1/glucagon peptide cohort (survodutide NEJM 47-62% MASH improvement, pemvidutide Best of EASL with cardiometabolic and fibrosis data, MetaVia DA-1726 9.1% weight loss) competed against THR-β agonism (Madrigal Rezdiffra, Aligos ALG-055009 46% liver fat), RNAi (Arrowhead ARO-INHBE), and FGF21 analogs (the Akero and 89bio programs that drew $5.2B and $3.5B acquisitions). On HBV/HDV: the entry-inhibitor peptides (Gilead's newly approved bulevirtide, Assembly's oral ABI-6250) shared the stage with gene editing (Precision PBGENE-HBV cccDNA elimination), epigenetic silencing (TUNE-401), capsid modulation plus ASO sequencing (Aligos), and therapeutic vaccines (Brii BRII-179). The combined week confirmed that liver disease is now a multi-mechanism therapeutic arena where peptides anchor the metabolic and entry-inhibitor lanes while gene and immune modalities pursue functional cure. ADA 2026 (June 5-8 New Orleans) is the next major readout window for the metabolic-peptide side.
EASL 2026 wraps in Barcelona Saturday May 30 after a week that confirmed MASH as a multi-mechanism therapeutic battleground. The GLP-1/glucagon peptide cohort delivered the headline data: Boehringer Ingelheim's survodutide full 48-week Phase 2 results in the NEJM (47-62% MASH improvement without fibrosis worsening, Phase 3 LIVERAGE enrolling); Altimmune's pemvidutide 48-week IMPACT data selected 'Best of EASL 2026' (triglycerides -23.7%, weight -7.5%, with HistoIndex qFibrosis fibrosis regression); MetaVia DA-1726 higher-dose Phase 1. The non-peptide cohort: Madrigal Rezdiffra eight-poster cardiovascular and portal-hypertension data, Aligos ALG-055009 THR-β (46.2% liver fat), Arrowhead ARO-INHBE RNAi (44% liver fat plus tirzepatide combination doubling weight loss), Galectin belapectin, Sagimet denifanstat. Novo Nordisk's ESSENCE Japanese and menopausal subgroups plus real-world burden data anchored the semaglutide MASH-labeling case. The week established that no single mechanism dominates MASH — GLP-1/glucagon leads on combined weight-plus-liver effect, THR-β and FGF21 lead on direct antifibrotic action, and combination therapy is the emerging 2027-2028 thesis.
Altimmune presented the full Week 48 top-line IMPACT Phase 2b oral data for pemvidutide in MASH today at EASL 2026 Barcelona (Dr. Mazen Noureddin, Houston Methodist Hospital, 17:00 CEST). The 1.8 mg dose reduced triglycerides 23.7%, total cholesterol 15.4%, body weight 7.5%, BMI 3.0 kg/m², and waist circumference 5.3 cm, alongside blood pressure reduction. Safety held at 48 weeks with roughly 1% discontinuation due to adverse events and mostly mild-to-moderate gastrointestinal events. Previously reported: 27.8% (1.2 mg) and 32.4% (1.8 mg) of patients achieved combined ELF and LSM improvements versus 3.2% on placebo. The 48-week analysis carries the 'Best of EASL 2026' designation. Pemvidutide is a balanced 1:1 GLP-1/glucagon dual receptor agonist peptide with FDA Fast Track + Breakthrough Therapy Designations for MASH. The cardiometabolic-risk-factor profile positions pemvidutide as differentiated on the lipid and cardiovascular axis versus pure GLP-1 agonists.
Boehringer Ingelheim's survodutide full 48-week Phase 2 MASH dataset published in the New England Journal of Medicine alongside the EASL 2026 presentation. MASH improvement without worsening of fibrosis occurred in 47% of the 2.4 mg group, 62% of the 4.8 mg group, and 43% of the 6.0 mg group, versus 14% on placebo. Up to 52% of survodutide-treated adults achieved significant improvement across fibrosis stages F1, F2, and F3 versus around 26% on placebo. Survodutide is an investigational long-acting glucagon/GLP-1 receptor dual agonist (BI 456906, partnered with Zealand Pharma) for once-weekly subcutaneous administration. The Phase 3 program is advancing through LIVERAGE (~1,800 adults with MASH F2-F3) and LIVERAGE-Cirrhosis (~1,590 adults with compensated MASH cirrhosis F4). Survodutide also posted 16.6% weight loss in the SYNCHRONIZE-1 obesity Phase 3 (April 2026). The NEJM publication is the strongest peer-reviewed validation of the GLP-1/glucagon dual mechanism in MASH to date.
Aligos Therapeutics presented positive data across ten presentations at EASL 2026 Barcelona. The headline MASH data: ALG-055009, a THR-β (thyroid hormone receptor beta) agonist small molecule, met its primary endpoint in the Phase 2a HERALD study with robust liver-fat reduction at week 12 — doses of 0.5 mg to 0.9 mg achieving statistically significant reductions with placebo-adjusted median relative reductions up to 46.2% as measured by MRI-PDFF. On the viral hepatology side, Aligos presented Phase 1 data on pevifoscorvir sodium suggesting a reduced cccDNA reservoir in chronic HBV patients, with an investigator-led study showing ≥24-week follow-up in HBeAg+ participants after 96 weeks of monotherapy. The combined slate spans the Aligos chronic HBV, HDV, MASH, and liver cancer pipeline. The ALG-055009 THR-β mechanism puts Aligos in direct competition with Madrigal's Rezdiffra (resmetirom), the only FDA-approved MASH therapy, on the same receptor target.
EASL 2026's first two days clarified the MASH-therapeutics competitive map across five mechanism classes. GLP-1/glucagon dual peptides: Altimmune pemvidutide (48-week IMPACT data, Best of EASL), Boehringer survodutide (NEJM 47-62% MASH improvement, LIVERAGE Phase 3), MetaVia DA-1726 (48 mg Phase 1). THR-β agonists: Madrigal Rezdiffra (only FDA-approved MASH therapy, eight EASL posters), Aligos ALG-055009 (46.2% liver-fat reduction Phase 2a). RNAi: Arrowhead ARO-INHBE (Activin E/ALK7, 44% liver fat, tirzepatide combination). FASN inhibition: Sagimet denifanstat + Rezdiffra combination. FGF21 analogs: the Akero efruxifermin (Novo $5.2B acquisition) and 89bio pegozafermin (Roche $3.5B acquisition) programs anchoring the most-acquired MASH mechanism. Plus galectin-3 inhibition (Galectin belapectin NAVIGATE) and pan-PPAR agonism (Inventiva lanifibranor NATiV3 Phase 3). The GLP-1/glucagon peptide class leads on combined weight-loss-plus-liver effect; the FGF21 and THR-β classes lead on pure antifibrotic mechanism. Combination therapy across mechanism classes is the emerging 2026 thesis.
Novo Nordisk extended its EASL 2026 ESSENCE presentation cycle into Day 2 with real-world evidence quantifying the MASH disease burden — documenting significant quality-of-life impairment and escalating healthcare costs in MASH patients — alongside the Japanese MASH and menopausal women subgroup analyses presented Day 1. The data builds the health-economic case for semaglutide 2.4 mg following the August 2025 FDA MASH-with-fibrosis approval. MASH affects roughly 1 in 3 people living with overweight or obesity worldwide, with the majority undiagnosed. Novo's 'Love Your Liver' EASL initiative offered on-site MASH testing for attendees. The real-world burden data complements the ESSENCE Phase 3 efficacy story by establishing the economic and quality-of-life rationale for early MASH intervention — a payer-facing argument as the GLP-1 MASH indication scales into 2026-2027 against the THR-β, FGF21, and GLP-1/glucagon competitor classes.
Altimmune released new analyses from the IMPACT Phase 2b trial today at EASL 2026 Barcelona. The late-breaking poster LBP-036 (Dr. Shaheen Tomah, 08:30 CEST) reported pemvidutide treatment produced concurrent improvements across multiple non-invasive tests of MASH activity and fibrosis, with HistoIndex qFibrosis digital-pathology analysis documenting significant fibrosis-stage improvements at 24 weeks versus placebo. The trial randomized 212 biopsy-confirmed MASH patients (F2-F3 fibrosis, with and without diabetes) to weekly subcutaneous pemvidutide 1.2 mg, 1.8 mg, or placebo over 48 weeks. Companion data on response analysis across NITs of liver inflammation/fibrosis and cardiovascular measures landed in additional posters. The abstract carries the EASL committee's 'Best of EASL 2026' top-tier selection. Pemvidutide is a 1:1 balanced GLP-1/glucagon dual receptor agonist peptide with FDA Fast Track + Breakthrough Therapy Designations for MASH; oral presentation Thursday May 28 at 17:00 CEST anchors the 48-week efficacy and safety data.
Novo Nordisk presented two ESSENCE Phase 3 subgroup analyses at EASL 2026 today. The Japanese MASH subgroup analysis extends the semaglutide 2.4 mg efficacy and safety case to Asian populations where MASLD and MASH develop at lower body-mass-index thresholds and involve distinct metabolic risk profiles. The Menopause subgroup analysis covers women in menopause, where hormonal changes accelerate liver disease progression and metabolic deterioration. Both analyses show consistent hepatic safety profile and efficacy across the underrepresented groups. The August 2025 FDA MASH-with-fibrosis approval of semaglutide 2.4 mg was based on the broader ESSENCE Phase 3 cohort; the EASL Day 1 presentations strengthen the global labeling case across non-Western populations and the menopausal-women subgroup that has historically been underrepresented in MASH clinical trials. Real-world evidence data presented today documents quality-of-life impairment and healthcare-cost escalation in MASH patients.
EASL 2026 Day 1 in Barcelona delivered the most concentrated MASH-therapeutics data cycle of 2026. The peptide-mechanism cohort: Altimmune pemvidutide qFibrosis fibrosis regression (LBP-036), MetaVia DA-1726 48 mg Phase 1 noninvasive liver assessment, Novo Nordisk ESSENCE Japanese/menopausal subgroups. The non-peptide-mechanism cohort: Arrowhead ARO-INHBE RNAi (Activin E/ALK7 pathway), Galectin Therapeutics belapectin NAVIGATE (galectin-3 inhibitor), Sagimet Biosciences denifanstat + resmetirom combination (FASN inhibitor + Madrigal's Rezdiffra), Madrigal eight-poster Rezdiffra data drop on cardiovascular and portal hypertension markers. The combined cycle reframes MASH as a multi-mechanism battleground rather than a single-class indication — GLP-1/glucagon peptides compete against thyroid-hormone-receptor agonism, RNAi, galectin-3 inhibition, FASN inhibition, and emerging combinations. Thursday May 28 brings the Altimmune pemvidutide oral presentation at 17:00 CEST; Friday May 29 brings ASCO opening in Chicago to anchor the parallel peptide-oncology cycle.
Altimmune confirmed the IMPACT Phase 2b 48-week analysis on pemvidutide in MASH was selected as a 'Best of EASL 2026' abstract — the highest-tier curated designation at the European Association for the Study of the Liver Congress. The oral presentation is scheduled Thursday May 28 at 17:00 CEST in Barcelona, complementing the late-breaking fibrosis-regression poster Wednesday May 27 08:30 CEST. The 'Best of EASL' selection elevates pemvidutide relative to the broader MASH-peptide slate at the meeting (Novo Nordisk's ESSENCE semaglutide liver safety, Boehringer Ingelheim's survodutide SYNCHRONIZE-1 forward-look, Madrigal's Rezdiffra portal hypertension data) and is the meeting committee's editorial signal that the IMPACT Phase 2b data set is among the highest-impact contributions to the congress.
Altimmune presents IMPACT Phase 2b clinical trial data on pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the Liver Congress 2026 (May 27-30 Barcelona). The randomized, placebo-controlled, double-blind Phase 2b trial enrolled 212 biopsy-confirmed MASH patients with fibrosis stages F2 or F3 (with and without diabetes), randomized 1:2:2 to weekly subcutaneous pemvidutide 1.2 mg, 1.8 mg, or placebo for 48 weeks. The late-breaking poster Wednesday May 27 at 08:30 CEST reports the AI-based Liver Explore quantitative digital pathology analysis showing significant reductions in proportionate areas of early, advanced, and total liver fibrosis at 24 weeks. The non-invasive PRO-C3:CTX-III ratio reduced consistent with fibrosis regression. Pemvidutide is a GLP-1/glucagon dual-action peptide with FDA Fast Track designation for MASH plus Breakthrough Therapy Designation. The approach competes directly with Boehringer Ingelheim's survodutide and Eli Lilly's retatrutide on the GLP-1/glucagon arm for MASH.
Madrigal Pharmaceuticals announced May 20 that multiple abstracts from its Rezdiffra (resmetirom) development and real-world evidence programs will be presented at EASL 2026 in Barcelona. Headline analyses include cardiovascular risk markers — secondary analysis of Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 examining improvements in Lp(a), LDL-C, and ApoB — and portal hypertension risk improvement in compensated MASH cirrhosis (F4c) measured by ANTICIPATE-NASH risk scores. Real-world evidence and noninvasive biomarker analyses round out the slate. Rezdiffra (a thyroid hormone receptor β agonist, not a peptide) was approved March 2024 as the first FDA-approved MASH therapy for noncirrhotic MASH with F2-F3 fibrosis. The EASL data extend the case toward compensated MASH cirrhosis and cardiovascular outcomes — a competitive context for the GLP-1/glucagon peptide programs (semaglutide ESSENCE, pemvidutide IMPACT, survodutide SYNCHRONIZE-1, retatrutide MASLD Phase 3) running on parallel tracks.
The European Association for the Study of the Liver (EASL) Congress 2026 opens Wednesday May 27 in Barcelona with a heavy peptide-MASH slate. Novo Nordisk's ESSENCE Phase 3 program leads with liver-safety subgroup analyses (Japanese MASH cohort, women in menopause), building on the August 2025 FDA approval of semaglutide for MASH-with-fibrosis. Eli Lilly's retatrutide MASLD Phase 3 (NCT06859268) is enrolling on the 86% Phase 2 liver-fat reduction baseline. Boehringer Ingelheim survodutide SYNCHRONIZE-1 Phase 3 MASH data is expected late 2026 with positive results potentially establishing the GLP-1/glucagon dual agonist as standard of care alternative to semaglutide. MetaVia's vanoglipel (DA-1241, GPR119 agonist) Phase 2a + resmetirom combination work presented at ECO 2025 anchors the combination-MASH therapy thesis. The EASL plenaries plus the May 21 TRIUMPH-1 readout reframe MASH as a peptide-mechanism battleground rather than a single-drug indication.
Eli Lilly's retatrutide MASLD Phase 3 program (NCT06859268) continues enrollment across multiple international sites following the December 2025 Phase 2 readout that documented 86% mean liver-fat reduction at 48 weeks on 12 mg dosing. The Phase 3 trial enrolls adults with biopsy-confirmed MASH stages F2-F3 with primary endpoint at week 52 measuring MASH resolution without worsening of fibrosis. The 86% liver-fat reduction substantially exceeds the resmetirom 38-46% benchmark from the MAESTRO-NAFLD-1 reference cohort. Topline data is expected H1 2027; full results at AASLD or EASL 2027. The MASLD Phase 3 sits alongside TRIUMPH-3 (obesity + CVD) and TRIUMPH-OUTCOMES (10,000-patient cardiovascular outcomes trial reading 2027) as the second 2027 retatrutide catalyst. If positive, retatrutide files for MASH labeling alongside the obesity NDA — potentially within the same FDA submission window.